The exploratory observational study of the usefulness of pemafibrate in lipid management of primary dyslipidemia

The exploratory observational study of the usefulness of pemafibrate in lipid management of primary dyslipidemia - PEMA-PD(PEMAfibrate-Primary Dyslipidemia)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052625

Enrollment

Registered

2023-11-01

Start date

2023-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dyslipidemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with diagnosed or suspected primary dyslipidemia (suspected CETP deficiency, HDL-C of 100 mg/dL or higher; suspected familial type III hyperlipidemia, following the diagnostic criteria in the Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.) 2) Patients who have received pemafibrate from May 2018 through the date of informed consent, or patients who will receive pemafibrate due to therapeutic need by September 30, 2024. 3) Patients at 18 years of age or older on the date of informed consent. 4) Patients who have given their written informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: Patients considered to be inappropriate for participation in this study at the discretion of principal investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
Change in triglyceride levels from baseline	—

Secondary

Measure	Time frame
Changes in lipids and various clinical parameters at each point. Adverse events and side effects.	—

Countries

Japan

Contacts

Public ContactDaisaku Masuda

Rinku General Medical Center Department of Cardiology

d-masuda@rgmc.izumisano.osaka.jp072-469-3111

Outcome results